API Holdings (Pharmeasy) Unlisted Shares
Naspers, Temasek get CCI approval to purchase stakes in PharmEasy
Mint
2 min read
PharmEasy Secures CCI Approval for Strategic Stake Acquisitions by Naspers and Temasek-Led Consortium, Reinforcing Investor Confidence in Healthcare Expansion
Expert Analysis:
Stakeholder Confidence:
PharmEasy gains CCI clearance for stake acquisitions by Naspers Group and Temasek.
Naspers Ventures BV, a Prosus subsidiary, plans additional API Holdings shares acquisition via a rights issue.
Diverse Investor Support:
Temasek, CDPQ Private Equity Asia, DBS Group, and Goldman Sachs India Alternative Investment Trust approved for API Holdings stakes.
Proposed transactions involve convertible preference shares (CCPS) subscriptions by various entities, signaling broad investor interest.
Strategic Alliances:
MacRitchie Investments (Temasek subsidiary) and EvolutionX (DBS-Temasek joint venture) participate in CCPS subscription.
Goldman Sachs India AIF Schemes underline the diverse financial backing PharmEasy attracts.
CCI-Approved Expansion:
PharmEasy's stake acquisitions by reputable entities receive CCI endorsement, affirming investor confidence.
Naspers Ventures BV and Temasek-led consortium's involvement signifies strong backing for PharmEasy's strategic growth and enhanced healthcare services.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved